Recibo

Recibo Therapeutics is a clinical-stage biotechnology company dedicated to developing transformative treatments for hearing loss and other inner ear disorders. The company's primary focus is on its lead candidate, ROT-101, a small molecule agonist of the Adenosine A3 receptor designed to treat noise-induced hearing loss (NIHL) and sudden sensorineural hearing loss. Backed by Frazier Healthcare Partners, Recibo leverages deep expertise in otology to address the biological mechanisms of cochlear damage and neuroprotection. The company has successfully advanced ROT-101 into Phase 1/2 clinical testing to evaluate its safety and potential to preserve hearing function. Recibo is headquartered in Salt Lake City, Utah, and operates as a specialized entity within the Frazier portfolio.